Lisa Bollinger - 03 Sep 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Reporting relationship: Director
Issuer ticker: APGE
Reported as of: 03 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Sep 2026, 16:39:09 UTC
Prior SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Batters, as attorney-in-fact for Lisa Bollinger

Key filing fact

Lisa Bollinger filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 03 Sep 2026.

Key facts

This page summarizes Lisa Bollinger's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 16:39.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002024557 Primary reporting owner

Bollinger Lisa

Relationship: Director
Address: C/O APOGEE THERAPEUTICS, INC., 1 LETTERMAN DRIVE, BUILDING B, SAN FRANCISCO
Signature: /s/ Matthew Batters, as attorney-in-fact for Lisa Bollinger
Signature date: 03 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -18,550
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,550
Exercise price: $47.86
Footnotes: F1, F2

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -8,112
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,112
Exercise price: $43.85
Footnotes: F1, F2

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -14,461
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,461
Exercise price: $41.66
Footnotes: F1, F2

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -7,657
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,657
Exercise price: $85.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Lisa Bollinger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.

Footnote F2

Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option.